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LONG-TERM IMMUNOLOGICAL STUDY ON POSTOPERATIVE ADjUVANT 
TREATMENT WITH INTERFERON-GAMMA IN PATIENTS WITH 
RENAL CELL CARCINOMA WHO UNDERWENT NEPHRECTOMY 
Hidenobu MIURAラ HirokiARAI， Akira MATSUOKAラ KoujiYAZAWAぅ
Eiichi SATOHラ KensakuNISHIMURAぅ MasahitoHONDA and Hideki FUJIOKA 
From the Dψαrtment 01 Urology， Osaka Police Hospital 
Previously， we reported the short-term immunological effects of postoperative adjuvant interferorト
gamma (IFNヴ)administration to renal cel carcinoma patients as determined by three-color註ow
cytometry. We now report the results of a long-term study on a larger number of subjects. 
Thirty“three patients with renal cel carcinoma received a prophylactic intramuscular injection of 
IFN聞γ(300X104 units per week) after nephrectomy. We evaluated immunological changes by 
measuring peripheral blood lymphocyte subsets including activated cytotoxic T lymphocytes (ACTL)， 
cytotoxic T lymphocytes (CTL)， activated suppressor T lymphocytes (ASTL)， helper T lymphocytes 
(HTL)ラactivatedsuppressor-inducer T lymphocytes (AITL)ラandsuppressor-inducer T lymphocytes 
(SITL). We also estimated the natural killer (NK) activity by a cytolytic test. Al1 33 patients were 
examined for a t leas t 12 mon ths after the s tart of 1 FN-γinjection， and 18 patients were examined for 
30 months including the 6-month period following discontinuation of IFN-γinjection. 
We found significant enhancement of the ACTL subset from the second week to the sixth 
month after the start of IFN-y injection. On the other hand， we found a significant decrease in 
the percentage of the HTL and SITL subsets for a long time after the start of injection. NK 
activity significantly increased throughout the period of administrationぅ andit continued to 
increase for six months after discontinuation of IFN-y injection. 
(Acta Urol. Jpn. 45: 79-83ラ 1999)
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(activated cytotoxic T lymphocytes :以下 ACTLと
略す)・細胞障害性Tリンパ球 (cytotoxicT lympho-
cytes: CTL)・活性化サプレッサー Tリンパ球
(activated suppressor T lymphocytes: ASTL) ， 
CD4陽性細胞のサブセットとしてヘルパ-Tリンパ
球 (helperT lymphocytes: HTL)・活性化サプレッ
サーインデューサ-Tリンパ球 (activatedsuppres叩
soトinducerT lymphocytes: AITL)・サプレッサー
インデューサー Tリンパ球 (suppressorωinducer T 
lymphocytes: SITL)の6項目である.各サブセット
の定義は， ACTL (CD8+ CDll b -HLA同DR+)，
CTL (CD8十 CDllb-HLA同DR-)， ASTL (CD8+ 
CDllb+ HLA-DR十)， HTL (CD4十 CD45RA
HLA悶DR一)AITL (CD4+ CD45RA + HLA同DR+)，
SITL (CD4 + CD45RA + HLA四DR-)である.ま
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Change of natural killer (NK) activityラ
before and after the start of IFN-y. 
Fig. 3. 
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われわれは既に threecolor flow cytometryを用い
た IFN-y投与後のより詳細な各サブセットの短期変
動を報告したがり，今回さらに症例を増やし長期間の


































































し，腎摘除術後，予防的に IFN-yを投与.し， three 
color flow cytometryを用いた投与前後の末梢血リン
パ球サブセットの変動と NK活性債の変動を長期的
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